The DDX platform uses a proprietary sugar to deliver large genetic payloads, unlike size-constrained viral vectors. This non-viral approach avoids immunogenicity, allowing for redosing, and relies on simple, available ingredients, which significantly simplifies manufacturing and lowers cost of goods.
Due to high unmet medical need in non-muscle invasive bladder cancer, the FDA created a special regulatory pathway. This guidance allows for full marketing approval based on a single-arm, open-label study of just 100 patients, dramatically accelerating the timeline and reducing the cost to bring new therapies to market.
While the FDA avoids providing an explicit number, analysis of previously approved drugs in this indication reveals a clear benchmark. A complete response (CR) rate of "about two-thirds" in the pivotal trial is the unofficial target companies like enGene must hit to be considered in the approvable range.